Sobre Mid-atlantic biotherapeutics (mabt)

Sobre companhia

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications.